Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitisDavid C. Whitcomb, Narcis Zarnescu, Nalini M. Guda et al.|Nature Genetics|2012Cited by 360
A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular CarcinomaRobin D. Tucker, Jill P. Smith|Digestive Diseases and Sciences|2019Cited by 19
Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular CancerMartha D. Gay, Jill P. Smith|Cancer Prevention Research|2020Cited by 19
Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor MicroenvironmentZoe X. Malchiodi, Jill P. Smith|Cancers|2021Cited by 14
Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse ModelJill P. Smith, Allen Cato|Cancer Prevention Research|2021Cited by 1